Abstract: In an embodiment, an object of the present invention is to provide a therapeutic and/or preventive agent for a fibrosis such as pulmonary fibrosis, an inflammatory disease and/or an aging disease. In an embodiment, the present invention relates to a therapeutic and/or preventive agent for at least one disease of a fibrosis, an inflammatory disease and an aging disease, comprising extracellular vesicle derived from cell of a tissue or a surrounding tissue thereof where disease can occur, in which the cell is differentiated cell, and relates to a pharmaceutical composition containing the therapeutic and/or preventive agent.

Abstract: An objective of the present invention is to provide effective methods for treating interstitial pulmonary diseases including interstitial pneumonia such as IPF. The present invention suggests that antibodies against HMGB-1 are effective for treating pulmonary fibrosis. Thus, the present invention provides preparations which comprise an anti-HMGB-1 antibody for treating interstitial pulmonary diseases.

Abstract: Preventives and remedies for diffuse lung diseases whereby apoptosis can be inhibited and thus favorable preventive/therapeutic effects can be established. These drugs contain apoptosis-inhibiting substances as the active ingredient. The above apoptosis-inhibiting substances include Fas antagonists and Fas/Fas ligand binding inhibitors such as Fas derivatives and anti-Fas ligand antibodies.